We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Read MoreHide Full Article
Amryt Pharma plc announced that the FDA has granted Orphan Drug designation to its marketed product, Mycapssa (oral octreotide), for the treatment of carcinoid syndrome, a common functional syndrome related to neuroendocrine tumors (NETs).
The Orphan Drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes one that affects fewer than 200,000 individuals in the United States.
Shares of Amryt were up in pre-market trading on Thursday following the announcement of the news. The stock has plunged 31.3% so far this year compared with the industry’s decline of 22%.
Image Source: Zacks Investment Research
Mycapssa is currently approved by the FDA as long-term maintenance treatment for acromegaly patients who have responded to and tolerated injectable treatment with octreotide or lanreotide. The medicine is also under review in Europe.
In the first quarter of 2022, Mycapssa generated revenues of $3.4 million. Successful development and potential approval for additional indications is likely to boost sales for Mycapssa in the days ahead.
Apart from Mycapssa, AMYT’s other marketed drugs include Myalept/Myalepta, Juxtapid/Lojuxta and Filzuvez (Oleogel-S10).
Myalept is approved as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Juxtapid is approved for treating homozygous familial hypercholesterolaemia.
Filsuvez is approved in the EU for the treatment of partial thickness wounds associated with junctional and dystrophic epidermolysis bullosa, a rare genetic skin disorder, in patients aged six months and older.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 6.9% for 2022 and 2% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Fate Therapeutics’ loss per share estimates narrowed 0.9% for 2022 and 0.5% for 2023 in the past 60 days.
Earnings of Fate Therapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. FATE delivered an earnings surprise of -0.72%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.7% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Amryt Pharma plc announced that the FDA has granted Orphan Drug designation to its marketed product, Mycapssa (oral octreotide), for the treatment of carcinoid syndrome, a common functional syndrome related to neuroendocrine tumors (NETs).
The Orphan Drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes one that affects fewer than 200,000 individuals in the United States.
Shares of Amryt were up in pre-market trading on Thursday following the announcement of the news. The stock has plunged 31.3% so far this year compared with the industry’s decline of 22%.
Image Source: Zacks Investment Research
Mycapssa is currently approved by the FDA as long-term maintenance treatment for acromegaly patients who have responded to and tolerated injectable treatment with octreotide or lanreotide. The medicine is also under review in Europe.
In the first quarter of 2022, Mycapssa generated revenues of $3.4 million. Successful development and potential approval for additional indications is likely to boost sales for Mycapssa in the days ahead.
Apart from Mycapssa, AMYT’s other marketed drugs include Myalept/Myalepta, Juxtapid/Lojuxta and Filzuvez (Oleogel-S10).
Myalept is approved as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Juxtapid is approved for treating homozygous familial hypercholesterolaemia.
Filsuvez is approved in the EU for the treatment of partial thickness wounds associated with junctional and dystrophic epidermolysis bullosa, a rare genetic skin disorder, in patients aged six months and older.
Zacks Rank & Other Stocks to Consider
Amryt currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) , Fate Therapeutics, Inc. (FATE - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , all carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 6.9% for 2022 and 2% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Fate Therapeutics’ loss per share estimates narrowed 0.9% for 2022 and 0.5% for 2023 in the past 60 days.
Earnings of Fate Therapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. FATE delivered an earnings surprise of -0.72%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.7% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.